Evaluation of epirubicin-loaded trastuzumabe-modified immunoliposomes and imunomagnetoliposomes in the breast cancer therapy

• Grant number: 21/04007-6
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• Start date: May 01, 2022
• End date: November 21, 2024
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Marlus Chorilli
• Grantee: Marcela Tavares Luiz
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Associated scholarship(s): 24/03389-0 - Evaluation of epirubicin-loaded trastuzumabe-modified immunoliposomes and imunomagnetoliposomes in the breast cancer therapy, BE.EP.PD

Abstract

Breast cancer accounts for approximately 11-12% of all diagnosed cancer worldwide, representing the main cause of death among women. Among them, about 20% of patients have overexpression of human epithelial receptor (HER2), which is associated with higher lethality and susceptibility to brain metastasis. Epirubicin (EPI) is a potent chemotherapeutic agent used in breast cancer treatment, however, the presence of multidrug resistance mechanisms and side effects have limited its therapeutic action. The loading of EPI in immunoliposomes functionalized with trastuzumab (antibody anti-HER2) is a strategy to improve the therapeutic efficacy through their active targeting for tumor cells. Furthermore, the association of immunoliposomes with magnetic nanoparticles (immunomagnetoliposomes) can also improve the delivery of EPI to tumoral tissue besides promoting cellular death by hyperthermia magnetic. In this context, the present study aims to develop, characterize and evaluate the in vitro and in vivo antitumoral activity of trastuzumab-modified and epirubicin-loaded immunoliposomes and immunomagnetoliposomes for breast cancer treatment. Physicochemical characterization of them will be performed through particle size, polydispersity index, zeta potential, encapsulation efficiency, trastuzumab integrity, functionalization efficiency, magnetization property, and electron microscopy. The in vitro antitumoral activity will be evaluated using bi-dimensional (2D) and three-dimensional (3D) cell cultures through cytotoxicity (resazurin) and uptake assays (confocal microscopy and flow cytometry). Furthermore, the in vivo efficacy will be performed using a xerographic model, with or without hyperthermia treatment.

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DE ARAUJO, PATRICIA ROCHA; SATO, MARIANA RILLO; LUIZ, MARCELA TAVARES; CHORILLI, MARLUS. Validation of an Innovative Chromatographic Method forHypericin Quantification in Nanostructured Lipid Carriers. JOURNAL OF AOAC INTERNATIONAL, v. N/A, p. 5-pg., 2023-09-06. (21/04007-6)

LUIZ, MARCELA TAVARES; DUTRA, JESSYCA APARECIDA PAES; VIEGAS, JULIANA SANTOS ROSA; DE ARAUJO, JENNIFER THAYANNE CAVALCANTE; TAVARES JUNIOR, ALBERTO GOMES; CHORILLI, MARLUS. Hybrid Magnetic Lipid-Based Nanoparticles for Cancer Therapy. PHARMACEUTICS, v. 15, n. 3, p. 21-pg., 2023-03-01. (21/04007-6)

LUIZ, MARCELA TAVARES; DI FILIPPO, LEONARDO DELELLO; DUTRA, JESSYCA APARECIDA PAES; VIEGAS, JULIANA SANTOS ROSA; SILVESTRE, AMANDA LETICIA POLLI; ANSELMI, CAROLINE; DUARTE, JONATAS LOBATO; CALIXTO, GIOVANA MARIA FIORAMONTI; CHORILLI, MARLUS. New Technological Approaches for Dental Caries Treatment: From Liquid Crystalline Systems to Nanocarriers. PHARMACEUTICS, v. 15, n. 3, p. 29-pg., 2023-03-01. (21/04007-6)